Hematology

The principal investigator at Seattle Children’s Research Institute discussed her lab’s work on using ultrasound mediated gene delivery to target hemophilia A.

Cell and gene therapies can transform the paradigm of care for patients with chronic, complex conditions, but these therapies come at an up-front cost of several million dollars per treatment, complicating the pipeline of access to them.

The Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison discussed the state of cell and gene therapy development.

Most participants maintained only over a 5% FVIII level after at least 15 months of follow-up.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The principal investigator at Seattle Children’s Research Institute discussed her lab’s preclinical research with UMGD for the treatment of hemophilia.

Both bluebird bio and Vertex Pharmaceuticals have received unfavorable opinions from the Office of the Inspector General on the matter.

After 3 tries, Mesoblast finally has a PDUFA date for its MSC therapy.

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.

Review top news and interview highlights from the week ending July 19, 2024.

The associate professor of medicine at University of Colorado discussed data presented at ASCO 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA announced its START Pilot Program in October 2023 with a similar goal.

Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment

In light of the CTN clearance, Interius expects to initiate plans for a phase 1 clinical trial (INVISE) for INT2104 within the final quarter of 2024.

Review top news and interview highlights from the week ending July 12, 2024.

GT Biopharma anticipates initiating the phase 1 clinical trial in the second half of 2024.

Tr1X reported that the first patient has cleared the trial’s safety period successfully, having experienced no serious adverse events.

The open-label, single-arm, multisite NEXICART-2 study will aim to enroll around 40 participants in total.

The associate professor of medicine at University of Colorado discussed how the field has shifted to support the growing use of CAR Ts and progress to come.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending July 5, 2024.

The associate professor of medicine at University of Colorado discussed a post hoc analysis study on subgroup analyses of liso-cel response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.